Kantrowitz described augmentation of coronary blood flow by retardation of the arterial pressure pulse in animal models in 1952.
In 1958, Harken suggested the removal of some of the blood volume via the femoral artery during systole and replacing it rapidly in diastole as a treatment for left ventricular (LV) failure, so called diastolic augmentation.
Percutaneous IABs in sizes 8.5-9.5 French (rather than 15 French used earlier) were introduced in 1979, and shortly after this, Bergman and colleaguesdescribed the first percutaneous insertion of IABP.
INDICATIONS FOR IABP Acute myocardial infarction Refractory LV failure Cardiogenic shock Refractory ventricular arrhythmias Acute MR and VSD Cardiomyopathies Catheterization and angioplasty Sepsis  Refractory unstable angina Infants and children with complex cardiac anomalies  Cardiac surgery Weaning from cardiopulmonary bypass
Contraindications FOR IABP Absolute Relative Aortic regurgitation Uncontrolled sepsis Aortic dissection Abdominal aortic aneurysm Chronic end-stage heart disease with no anticipation of recovery Tachyarrhythmias Aortic stents Severe peripheral vascular disease Major arterial reconstruction surgery
Complications associated with IABP Transient loss of peripheral pulse Limb ischaemia Thromboembolism Compartment syndrome  Aortic dissection Local vascular injury—false aneurysm, haematoma, bleeding from the wound Infection Balloon rupture (can cause gas embolus) Balloon entrapment Haematological changes, for example thrombocytopenia, haemolysis Malpositioning causing cerebral or renal compromise Cardiac tamponade
DETROIT – Dr. Adrian Kantrowitz, a cardiac surgeon who performed the nation’s first human heart transplant and who also developed lifesaving medical implants, has died. He was 90.
Kantrowitz died Friday in Ann Arbor of complications from heart failure, said his wife, Jean Kantrowitz.
In 1967, Kantrowitz performed the first human heart transplant in the United States, three days after the world’s first was performed in South Africa.
But the transplant, on an infant who died several hours later, was only a small part of his life’s work to solve the problem of heart failure, his wife said.
Adrian Kantrowitz invented and for decades continued to improve the left ventricular assist device, or LVAD, which would later lend its name to his Detroit-based research company, L-VAD Technology Inc.